Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) is developing Amitiza in collaboration with its partner Takeda Pharmaceuticals, which markets the drug in the United Stats. Amitiza sales from the U.S. came in at $78.0 million, up 4.6% year over year. Total prescriptions for Amitiza increased 5% in 2013 and 6% in the fourth quarter in the U.S. The drug already has FDA approval for three conditions, and the company has recently filed for a fourth. The Cantor Fitzgerald price target is $12, and the consensus target is $10.25 (edit: now over $11 on Yahoo). Sucampo was trading at $8.30 on Friday. A move to the target would be a 45% gain.
Read more: Low-Priced Biotech Stocks That Could Double (or More) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/03/08/low-priced-biotech-stocks-that-could-double/#ixzz2veumJG2i
Follow us: @247wallst on Twitter | 247wallst on Facebook
This is a great investment.Upgrades for sure.
It was mentioned that Dr. Uneo and his wife own 25 million shares out of the 41 million share float, and slumdog still doesn't get it. So, I'll help old slumdog and make it clear. Dr. Uneo completely controls this company with his share ownership. If he is retiring, it is through his wishes and not the BOD. This is what he wants to do. He is convinced that this move will add share holder value. And guess what? He is the largest shareholder!
They own it
Sucampo Pharmaceuticals (NASDAQ:SCMP) CEO Ryuji Ueno unloaded 360,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $10.36, for a total transaction of $3,729,600.00. Following the completion of the sale, the chief executive officer now directly owns 148,530 shares of the company’s stock, valued at approximately $1,538,771. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 10.58 on Thursday. Sucampo Pharmaceuticals has a 52 week low of $4.55 and a 52 week high of $11.00. The stock has a 50-day moving average of $8. and a 200-day moving average of $7.01. The company has a market cap of $442.9 million and a P/E ratio of 24.95.
SCMP has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald cut their price target on shares of Sucampo Pharmaceuticals from $11.00 to $10.00 in a research note to investors on Thursday, November 7th. They now have a “buy” rating on the stock. Analysts at Zacks upgraded shares of Sucampo Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, November 6th. They now have a $7.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $9.20.
Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.
Look at the chart of DNDN. Ariad will follow it...
Sentiment: Strong Buy
and you have a discounted share price of $15 per share.. Now..
Sentiment: Strong Buy
The 90% ownership issue will be the thing that rams them.
the sales results are just ahead of us, which will move us up sharply
Seems to be..
I would expect a buyout will be attempted, but that will not be possible..
Looks good from here..
Listen to the last Sucampo CC to obtain a better understanding.. Your 3X is nonsense..